Betta Pharmaceuticals (300558) Fundamentals 2026 — P/E 58.0x, Revenue Analysis | SniperIQ
Betta Pharmaceuticals (300558) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥25.5B, trading at ¥60.71 on the SHZ. This SniperIQ fundamentals page covers Betta Pharmaceuticals's valuation (P/E 58.0x, P/B 3.8x), profitability (net margin 11.8%), revenue (¥3.6B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Betta Pharmaceuticals's market cap?
Betta Pharmaceuticals (300558) has a market capitalization of approximately ¥25.5B, trading at ¥60.71 on the SHZ. Market cap moves with the live share price.
What is Betta Pharmaceuticals's P/E ratio?
Betta Pharmaceuticals's trailing twelve-month P/E ratio is 58.0x, with a price-to-book (P/B) of 3.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Betta Pharmaceuticals?
Betta Pharmaceuticals runs a net profit margin of 11.8%, a gross margin of 79.0%, and an operating margin of 15.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Betta Pharmaceuticals generate?
Betta Pharmaceuticals reported revenue of ¥3.6B for fiscal year 2025, with net income of ¥305M and earnings per share (EPS) of 0.73. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Betta Pharmaceuticals pay a dividend?
Betta Pharmaceuticals offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Betta Pharmaceuticals financially healthy?
Betta Pharmaceuticals carries a debt-to-equity ratio of 0.38x and a current ratio of 0.99x, with a market beta of 0.51. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Betta Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Betta Pharmaceuticals (300558) the key facts are: market cap ¥25.5B, P/E 58.0x, revenue ¥3.6B, 52-week range 40.1-79.8. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Betta Pharmaceuticals's full fundamentals live
Get Betta Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.